Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bausch + Lomb and Paragon BioTeck have signed a licensing deal for the commercialization and distribution of phenylephrine in the US.
Subscribe to our email newsletter
The alpha-1 adrenergic receptor agonist Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% and 10% is indicated for dilation of the pupil due to its vasoconstrictor and mydriatic action.
Bausch + Lomb global pharmaceuticals president Dan Wechsler said, "This agreement with Paragon demonstrates Bausch + Lomb’s commitment to partnering with companies with eye health products that can benefit from our commercial capabilities."
Phenylephrine works by constricting ophthalmic blood vessels and the radial muscle of the iris there by acting as a potent vasoconstrictor.
Paragon BioTeck president and CEO Patrick Witham said, "We are enthusiastic about embarking on this new relationship with Bausch + Lomb, as this level of collaboration is consistent with Paragon’s ongoing commitment to further develop and foster an unparalleled network of collaborative partners."